Fact Sheet Q1|17
Investment Highlights
Company Profile
1
2
3
4
5
Sartorius Stedim Biotech is a leading provider of cutting-edge
equipment and services for the development, quality assurance
and production processes of the biopharmaceutical industry. Its
integrated solutions and focus on single-use technologies are
supporting biopharma companies around the world to develop
and produce drugs safely, timely and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech employs
more than 4,700 people in more than 20 countries.
Key Figures
Clear focus on fast growing businesses, especially the highly
attractive biopharma market
More than 85% of sales generated from global TOP
1-3 position
Strong base in all growth regions; Asia accounts for
around 20% of sales
Scalable business model with attractive incremental
margins
Proven track record with alliances and acquisitions
Q1 2017
Q1 2016
Δ in %
2016
2015
268.8
302.1
71.9
26.7
44.0
0.48
61.9
0.3
245.8
274.1
64.6
26.3
39.4
0.43
60.9
0.3
+8.2
+9.0
+11.2
1,051.6
1,080.8
288.7
27.5
176.6
1.92
63.9
0.2
884.3
946.4
231.3
26.2
139.3
1.51
60.7
0.4
In millions of € unless otherwise specified
Sales revenue (Δ in const. fx)
Order intake (Δ in const. fx)
Underlying EBITDA 1
Underlying EBITDA 1 as % of sales revenue
Underlying net profit after non-controlling interest 2
Earnings per share 2,3 in €
Equity ratio in %
Ratio of net debt to underlying EBITDA 1
1
+11.5
+11.6
1 Underlying
EBITDA = earnings before interest, taxes, depreciation and amortization, and adjusted for extraordinary items 2 Underlying net profit = net
profit after non-controlling interest; adjusted for extraordinary items, amortization and based on a normalized financial result and tax rate 3 2015
adjusted for stock split; rounded values
Sales by Region 2016
Sales and Earnings Development
1,200
EMEA
683.5
23.5
884.3
26.2
1,051.6
27.5
2012
2013
2014
2015
2016
600
Asia | Pacific
37%
588.4
23.0
900
43%
Americas
544.0
21.5
20%
300
0
EMEA = Europe | Middle East | Africa
Sales revenue
Outlook
Earnings per Share1 in €
2.00
0.70
0.82
Underlying EBITDA margin in %
0.95
1.51
1.92
1.50
1.00
0.50
FY 2016
FY 2017
Sales revenue growth1
20.4%
~ 8% - 12%
Underlying EBITDA margin1,2
27.5%
~ +0.5 pp
Capex ratio
7.6%
~ 10% - 13%
1
In constant currencies 2 Underlying = adjusted for extraordinary items
0.00
2012
1
2013
2014
2015
2016
Underlying net profit = net profit after non-controlling interest; adjusted
for extraordinary items, amortization and based on a normalized financial
result and tax rate; 2012 to 2015 adjusted for stock split, rounded values
1|2
Fact Sheet Q1|17
Strategy
 Positioned as a total solution provider for the biopharma
 One of the widest portfolios in the industry with a clear
industry with a product portfolio covering nearly all steps of
the customers’ production processes
focus on single-use technologies such as filters, bags and
cell culture media
 Global
leading positions in key technology platforms;
e.g. process filtration, fluid management, fermentation and
membrane chromatography
 Regionally focused on gaining market share in North
America and leveraging our strong market growth in Asia
 Continuous expansion through complementary acquisitions
and alliances
Facts about the Share
Ticker symbol: DIM
Ticker symbol Bloomberg: DIM:FP
Sartorius Stedim Biotech Share (indexed)
April 1, 2016, to March 31, 2017
130
Ticker symbol Reuters: STDM.PA
ISIN: FR0013154002
Liquidity provider: Gilbert Dupont
115
Stock exchange: Euronext Paris
Market segment: Local Securities –
Compartement A (Large Caps)
Indexes: SBF 250, SBF 120, CAC ALL
SHARES, CAC MID & SMALL, CAC
SMALL, CAC HEALTH CARE
100
85
70
Apr. 2016
Mar. 2017
Sartorius Stedim Biotech
Shareholder Structure
CAC MID & SMALL
SBF 120
NASDAQ Biotech Index
Financial Calendar
as of December 31, 2016
Sartorius AG
~74%
~85% of voting rights
Free float
~26%
~15% of voting rights
July 21, 2017
Publication of first-half 2017 results
October 24, 2017
Publication of nine-month 2017 results
January 2018
Publication of preliminary full-year 2017 results
April 3, 2018
Annual Shareholders‘ Meeting in Aubagne
Disclaimer
This fact sheet contains statements concerning the Sartorius Group’s future performance. These statements are based on assumptions and estimates.
Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because
our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to
update our forward-looking statements. Throughout this fact sheet, differences may be apparent as a result of rounding during addition.
Contact
Petra Kirchhoff | Vice President
Corporate Communications & Investor Relations
Phone: +49.551.308.1686
[email protected]
Andreas Theisen | Director
Investor Relations
Phone: +49.551.308.1668
[email protected]
2|2